The 11-amino-acid fragment of erythropoietin stripped of the red-blood-cell side effect — a tissue-protective peptide in active clinical development for diabetic neuropathy and sarcoidosis.
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin (EPO). It was engineered to preserve EPO’s tissue-protective effects (via the innate repair receptor, IRR) while eliminating its red-blood-cell-stimulating effect.
Developed by Araim Pharmaceuticals and currently in mid-stage clinical trials for diabetic neuropathic pain, sarcoidosis-related small fiber neuropathy, and other cell-protection indications. Not FDA approved yet; trials ongoing.
Not FDA approved. Phase 2/3 clinical trials active. Not WADA prohibited (non-hematopoietic, doesn’t raise RBC count).
Binds the heteromeric IRR (EPO-receptor + β-common-receptor complex) expressed on injured tissues, immune cells, and peripheral nerves. Triggers tissue repair, anti-inflammatory, and anti-apoptotic signaling.
Doesn’t bind the classical EPO receptor dimer on erythroid cells — so no erythropoiesis, no hematocrit rise, none of EPO’s cardiovascular risks. This is the key engineering advantage.
Particularly studied for peripheral nerve repair in diabetic neuropathy and sarcoidosis-related small fiber neuropathy — conditions with few good treatment options.
| Benefit | Evidence |
|---|---|
| Diabetic neuropathy pain | Phase 2 studies: improved nerve fiber density and reduced pain scores |
| Sarcoidosis SFN | Open-label data in sarcoidosis-associated small fiber neuropathy: meaningful symptom improvement |
| Wound healing | Preclinical data for accelerated chronic wound closure |
| Anti-inflammatory | Broad anti-inflammatory via IRR signaling without suppressing normal immune function |
| Ischemia/reperfusion protection | Preclinical data in kidney, heart, and CNS |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeClinical trials have used 1–8 mg SubQ daily, with 4 mg as the primary arm in the pivotal Phase 2b trial (PMID 28475703, 28-day duration) and up to 12 weeks (84 days) in the DME trial (PMID 32674280). Nerve-related improvements were significant at 28 days in the pivotal sarcoidosis SFN trial; longer observation windows are still being explored in ongoing studies.
10 mg vial + 2 mL BAC water = 5 mg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 2 mg | 0.40 mL | 40 units |
| 4 mg | 0.80 mL | 80 units |
Use our free peptide calculator to figure out your reconstitution volume, draw amount, and syringe units.
Open Peptide CalculatorDosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
ARA-290 has a remarkably clean side-effect profile in trials — the whole point of engineering out the erythropoietic activity was to avoid EPO’s cardiovascular baggage.
ARA-290 (Cibinetide) is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
StackTrax’s preferred partner NextGen Peptides does not currently carry ARA-290 (Cibinetide)in their catalog, which is why you don’t see a direct purchase link here. Other major research-chemical suppliers carry it; we don’t specifically recommend one for this compound.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDisclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.